Results 131 to 140 of about 9,189 (185)

Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial

Background: There is a need for additional therapeutic options for serious infections caused by Gram-negative pathogens. In the phase 3, descriptive REVISIT study, we investigated the safety and efficacy of aztreonam–avibactam in the treatment of ...
Leaney, Joanne L, Carmeli, Yehuda, Aksoy, Firdevs, Pypstra, Rienk, Liang, Lu, Jiménez-Rodríguez, Rosa-María, Gumenchuk, Illia, Wible, Michele, Torre-Cisneros, Julian, Arhin, Francis F, Zhao, Yongjie, Cisneros, José Miguel, Luckey, Alison, Chow, Joseph W, Wang, Minggui, Daikos, George L, Chen, Gang, Singer, George, Paul, Mical, Pyptiuk, Oleksandr, Titov, Ivan, Rogers, Halley   +21 more
core  

Targeting carbapenem-resistant and hypervirulent Klebsiella pneumoniae: in vitro evaluation of cefepime/zidebactam, aztreonam/avibactam, imipenem/relebactam, and meropenem/vaborbactam. [PDF]

BMC Infect Dis
Li Y, Li Y, Jia X, Mao H, Li D, Zhang J.
europepmc   +1 more source

Continuous Infusion of Aztreonam-Avibactam After High Loading Dose for an Infection Caused by an OXA-48- and NDM-1-Co-producing ST147 Klebsiella pneumoniae. [PDF]

Infect Dis Ther
Laffont-Lozes P, Villa F, Mory C, Sotto A, Loubet P, Pantel A, Larcher R.   +6 more
europepmc   +1 more source

Aztreonam Acts as a Synergist for Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacteriaceae (CRE) of Various Carbapenemase Phenotypes in Southwestern China

Xuelian Ruan,1,* Zhiyu Gong,1,* Moqiyi Zeng,1 Ziqing Zhong,1 Yongling Chen,1 Fangyi Wei,1 Chong Lei,1 Yuanyuan Zhu,1 Xue Qin,1 Meng Li1,2 1Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Key
Ruan X, Zhu Y, Zeng M, Wei F, Qin X, Chen Y, Gong Z, Zhong Z, Lei C, Li M   +9 more
core  

Comparative <i>in vitro</i> efficacy of aztreonam-avibactam and other alternatives (cefepime-taniborbactam, cefepime-zidebactam, and cefiderocol) against metallo-β-lactamase-producing Enterobacterales isolated in 2024 in France. [PDF]

Antimicrob Agents Chemother
Emeraud C, Dutkiewicz M, Dortet L.
europepmc   +1 more source

Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023). [PDF]

J Antimicrob Chemother
Sader HS, Kimbrough JH, Winkler ML, Castanheira M, Mendes RE.   +4 more
europepmc   +1 more source

Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta-Lactamase-Producing Enterobacterales Infections in Spain Using the STEDI AMR Value Framework. [PDF]

Infect Dis Ther
Ferrer R, Luque S, Martínez-Martínez L, de Lossada A, Maroto-Diaz M, Moya-Alarcón C, de Ceano-Vivas MC, Moreno Y, Dennis J, Nikolova S, Zormpas E, Broughton E, Gheorghe M.   +12 more
europepmc   +1 more source

PHARMACOKINETICS/PHARMACODYNAMICS OF A 8-LACTAM AND /8-LACTAMASE INHIBITOR COMBINATION: A NOVEL APPROACH FOR AZTREONAM/AVIBACTAM

Антибиотики и Химиотерапия, 2020
R. .. Singh, A. .. Kim, M. A. Tanudra, J. J. Harris, R. E. Mclaughlin, S. .. Patey, J. P. O'donnell, P. A. Bradford, A. E. Eakin   +8 more
openaire   +1 more source

Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Colistin + Meropenem (COL + MER) for the Treatment of Infections Caused by Metallo-β-Lactamase (MBL)-Producing Enterobacterales in Italy. [PDF]

Pharmacoeconomics
Falcone M, Bao X, Woodcock F, Di Virgilio R, Vidal Pereira MA, Kantecki M, Gheorghe M.   +6 more
europepmc   +1 more source